

# Thomas J Kaley

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3612265/thomas-j-kaley-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47  
papers

5,084  
citations

27  
h-index

47  
g-index

47  
ext. papers

6,976  
ext. citations

6.1  
avg, IF

4.86  
L-index

#	Paper	IF	Citations
47	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , <b>2019</b> , 51, 202-206	36.3	1435
46	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , <b>2017</b> , 2017,	3.6	699
45	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , <b>2019</b> , 25, 477-486	50.5	490
44	Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. <i>Journal of Neurosurgery</i> , <b>2015</b> , 122, 4-23	3.2	327
43	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. <i>Cancer Discovery</i> , <b>2017</b> , 7, 1018-1029	24.4	201
42	R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. <i>Blood</i> , <b>2015</b> , 125, 1403-10	2.2	190
41	Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. <i>Neuro-Oncology</i> , <b>2015</b> , 17, 116-21	1	153
40	BRAF Inhibition in -Mutant Gliomas: Results From the VE-BASKET Study. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3477-3484	2.2	139
39	Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 283-90	1	135
38	Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 829-40	1	134
37	Therapy of chemotherapy-induced peripheral neuropathy. <i>British Journal of Haematology</i> , <b>2009</b> , 145, 3-14	4.5	134
36	Atypical and anaplastic meningiomas treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , <b>2012</b> , 109, 187-93	4.8	119
35	Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , <b>2015</b> , 125, 183-90	4.8	83
34	Central Nervous System Cancers, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 1191-202	7.3	74
33	Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. <i>Neuro-Oncology</i> , <b>2013</b> , 15, 242-50	1	71
32	Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5023-31	12.9	70
31	Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 4786-4796	12.9	69

30	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. <i>Neurology</i> , <b>2015</b> , 84, 280-6	6.5	62
29	Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 26-36	1	54
28	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3610-8	12.9	53
27	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5537-5547	12.9	48
26	A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , <b>2015</b> , 17, 1386-92	1	39
25	T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor VIII Status. <i>American Journal of Neuroradiology</i> , <b>2015</b> , 36, 2256-61	4.4	35
24	Temozolomide or bevacizumab for spinal cord high-grade gliomas. <i>Journal of Neuro-Oncology</i> , <b>2012</b> , 109, 385-9	4.8	35
23	Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , <b>2016</b> , 130, 571-579	4.8	32
22	Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 99, 797-804	4	27
21	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1702-1709	2.2	27
20	Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , <b>2019</b> , 144, 403-407	4.8	23
19	Dropped head syndrome: report of three cases during treatment with a MEK inhibitor. <i>Neurology</i> , <b>2012</b> , 79, 1929-31	6.5	21
18	Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 1380-1390	1	20
17	Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 735-43	1	20
16	Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. <i>Annals of Clinical and Translational Neurology</i> , <b>2020</b> , 7, 429-436	5.3	13
15	Whole-brain radiotherapy in patients with brain metastases from melanoma. <i>CNS Oncology</i> , <b>2014</b> , 3, 401-6	4	13
14	Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 18, 1571-1578	7.3	9
13	Bevacizumab for acute neurologic deterioration in patients with glioblastoma. <i>CNS Oncology</i> , <b>2013</b> , 2, 413-8	4	7

12	Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas. <i>Journal of Neuro-Oncology</i> , <b>2019</b> , 145, 57-63	4.8	6
11	DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy. <i>Journal of Neuro-Oncology</i> , <b>2020</b> , 146, 339-346	4.8	4
10	Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab. <i>CNS Oncology</i> , <b>2018</b> , 7, 7-13	4	3
9	Value of [F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, vdaa050	0.9	2
8	Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhage. <i>Neuro-Oncology Practice</i> , <b>2017</b> , 4, 24-28	2.2	2
7	ACTR-43. PILOT STUDY OF OPTUNE (NOVOTTF-100A) FOR RECURRENT ATYPICAL AND ANAPLASTIC MENINGIOMA. <i>Neuro-Oncology</i> , <b>2016</b> , 18, vi11-vi11	1	2
6	Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma. <i>CNS Oncology</i> , <b>2018</b> , 7, CNS19	4	2
5	Biology and Treatment of Meningiomas: A Reappraisal. <i>Hematology/Oncology Clinics of North America</i> , <b>2022</b> , 36, 133-146	3.1	1
4	Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity. <i>Pancreatology</i> , <b>2021</b> , 21, 599-605	3.8	1
3	Radiographic Assessment of Meningiomas <b>2020</b> , 25-33		
2	ACTR-03. SAFETY AND FEASIBILITY OF RAPID RITUXIMAB INFUSIONS IN PATIENTS WITH PRIMARY CNS LYMPHOMA. <i>Neuro-Oncology</i> , <b>2016</b> , 18, vi1-vi1	1	
1	Neurologic Complications of Chemotherapy and Radiation Therapy <b>2021</b> , 521-537		